Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA192357
Max Phase: Preclinical
Molecular Formula: C21H25FO4
Molecular Weight: 360.43
Molecule Type: Small molecule
Associated Items:
ID: ALA192357
Max Phase: Preclinical
Molecular Formula: C21H25FO4
Molecular Weight: 360.43
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CCOc1cc(/C=C\c2ccc(OC)c(F)c2)cc(OCC)c1OCC
Standard InChI: InChI=1S/C21H25FO4/c1-5-24-19-13-16(14-20(25-6-2)21(19)26-7-3)9-8-15-10-11-18(23-4)17(22)12-15/h8-14H,5-7H2,1-4H3/b9-8-
Standard InChI Key: RJQUGRQWWZIMER-HJWRWDBZSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 360.43 | Molecular Weight (Monoisotopic): 360.1737 | AlogP: 5.20 | #Rotatable Bonds: 9 |
Polar Surface Area: 36.92 | Molecular Species: NEUTRAL | HBA: 4 | HBD: 0 |
#RO5 Violations: 1 | HBA (Lipinski): 4 | HBD (Lipinski): 0 | #RO5 Violations (Lipinski): 1 |
CX Acidic pKa: | CX Basic pKa: | CX LogP: 4.90 | CX LogD: 4.90 |
Aromatic Rings: 2 | Heavy Atoms: 26 | QED Weighted: 0.58 | Np Likeness Score: -0.46 |
1. Ducki S, Mackenzie G, Lawrence NJ, Snyder JP.. (2005) Quantitative structure-activity relationship (5D-QSAR) study of combretastatin-like analogues as inhibitors of tubulin assembly., 48 (2): [PMID:15658859] [10.1021/jm049444m] |
Source(1):